Lanjing Wei, Qi Zhang, Cuncong Zhong, Lily He, Yuxia Zhang, Ahlam M Armaly, Jeffrey Aubé, Danny R Welch, Liang Xu, Xiaoqing Wu
Chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), however, chemoresistance compromises its efficacy. The RNA-binding protein Hu antigen R (HuR) could be a potential therapeutic target to enhance the chemotherapy efficacy. HuR is known to mainly stabilize its target mRNAs, and/or promote the translation of encoded proteins, which are implicated in multiple cancer hallmarks, including chemoresistance. In this study, a docetaxel-resistant cell sub-line (231-TR) was established from the human TNBC cell line MDA-MB-231...
June 26, 2023: Molecular Oncology